CVM CEL-SCI
- 2.050
- +0.380+22.75%
CEL-SCI News
CEL-SCI Gains as FDA Greenlights Confirmatory Study for Multikine
CEL-SCI Receives FDA Approval For Its Confirmatory Study Of Multikine For The Treatment Of Head & Neck Cancer
Critical milestone achieved—the FDA accepted CEL-SCI's selection criteria defining the Multikine target population before surgerySelected patient population had 73% survival with Multikine vs. 45% wit
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
Critical milestone achieved—the FDA accepted CEL-SCI's selection criteria defining the Multikine target population before surgery Selected patient population had 73% survival with Multikine vs. 45% without Multikine
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersRepare Therapeutics (NASDAQ:RPTX) shares rose 34.1% to $4.4 during Wednesday's pre-market session. The company's market cap stands at $186.7 million. The company's, Q1 earnings came out yesterd
Cel-Sci Corp Bolsters Board With Finance Expert Mario Gobbo
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
CEL-SCI Corporation (NYSE American: CVM) today announced the appointment of Mario Gobbo to its Board of Directors.
CEL-SCI Advances Cancer Therapy, Completes Manufacturing Facility
Express News | CEL-SCI Q1 EPS $(0.14) Up From $(0.18) YoY
Cel-Sci GAAP EPS of -$0.14
Press Release: CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results VIENNA, Va.--(BUSINESS WIRE)--February 15, 2024-- CEL-SCI Corporation (NYSE American: CVM) today reported financial results fo
CEL-SCI 1Q Loss/Shr 14c >CVM
CEL-SCI 1Q Loss/Shr 14c >CVM
Cel-Sci Corp. Secures Funding for Multikine Development
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a Phase 3 cancer immunotherapy company, today announced the closing of its previously announced public offering of 3,875,000 shares of its common stock at a
12 Health Care Stocks Moving In Friday's Intraday Session
GainersIntelligent Bio Solutions (NASDAQ:INBS) shares moved upwards by 219.4% to $9.2 during Friday's regular session. The market value of their outstanding shares is at $6.6 million. NanoString Techn
Why CEL-SCI Corporation (CVM) Shares Are Diving
CEL-SCI Corporation (NASDAQ:CVM) shares are trading lower by 13.9% to $2.46 Friday morning after the company priced an offering of 3.875 million shares shares of its common stock at $2.00 per share, t
Express News | Cel-Sci Shares Are Trading Lower After the Company Announced Pricing of a $7.75 Million Public Offering of 3.875 Million Shares of Common Stock at $2 per Share
CEL-SCI Slides After Follow-on Offering Prices Below Market Price
By Rob Curran Shares of CEL-SCI slid after the cancer-drug developer priced a follow-on offering of 3.9 million shares well below its Thursday closing price. CEL-SCI slid 23% to $2.20 in premarket t
Express News | CEL-SCI Announces Pricing Of $7.75M Public Offering Of 3.875M Shares Of Common Stock At $2.00/Share
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of an offering of 3,875,000 shares of its common stock at an offering price of $2.00 per
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
Marks key achievement that is a prerequisite to filing a Biologics License Application with the FDA and other regulators for marketing approval CEL-SCI Corporation (NYSE:CVM) today reported that its Multikine
Analysis
Price Target
No Data
